The Ripple Effect Podcast #159 (Dr. Thomas Seyfried | Keto & Cancer: Manage & Prevent Disease)

Dr. Thomas Seyfried joins us to talk about his book Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer, and also to talk about his research at Boston College which focuses on mechanisms by which metabolic therapy manages chronic diseases such as epilepsy, neurodegenerative lipid storage diseases, and cancer. The metabolic therapies include caloric restriction, fasting, and ketogenic diets. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet, and experts in the cancer research field have praised this comprehensive study as one of science's hottest topics.Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master’s degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications.